OXA-23 Drives Carbapenem-Resistant Acinetobacter in Baghdad Isolates

This single-center molecular surveillance study quantifies OXA-type carbapenemase gene prevalence and phenotypic resistance in Acinetobacter baumannii, reinforcing colistin and tigecycline as the last-line options for pharmacists managing carbapenem-resistant infections.

Acinetobacter baumanniiOXA carbapenemaseblaOXA-23blaOXA-24blaOXA-51blaOXA-58carbapenem resistancecolistintigecyclineimipenemmeropenemmolecular epidemiologyantimicrobial stewardshipCRABIraq Infectious Disease / Antimicrobials

Background Information

Carbapenem resistance in Acinetobacter baumannii emerges as a public health crisis.

Acinetobacter baumannii is a major cause of hospital-acquired infections with increasing resistance to carbapenems, posing a significant public health challenge. Carbapenem resistance was high at 83.3% for imipenem and 72.2% for meropenem, with blaOXA-51 found in 100%, blaOXA-23 in 86.1% of isolates. The study highlights the need for molecular surveillance and antimicrobial stewardship to combat multidrug-resistant Acinetobacter baumannii in healthcare settings, particularly where these resistance genes are prevalent. Molecular surveillance and stewardship are crucial as carbapenem resistance spreads through blaOXA genes in Acinetobacter baumannii.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Abdulhassan AA, Hamid HH, Al-Lami SM, Saber ZM

Citation: Abdulhassan AA, Hamid HH, Al-Lami SM, et al. Molecular Characterization of OXA Carbapenemase Genes in Acinetobacter Baumannii Isolated from Different Clinical Samples. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2026;60(4):445-457. doi:10.33594/000000882

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being revised. Our first draft did not meet our editorial bar, so it is going back through review before it publishes.